Patents by Inventor Dauphine Barone

Dauphine Barone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130259799
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Application
    Filed: June 11, 2013
    Publication date: October 3, 2013
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • Patent number: 8481704
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: July 9, 2013
    Assignee: Amgen Inc.
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • Publication number: 20130071923
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Application
    Filed: August 20, 2012
    Publication date: March 21, 2013
    Applicant: Amgen Inc.
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • Patent number: 8268311
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: September 18, 2012
    Assignee: Amgen Inc.
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • Publication number: 20110189082
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Application
    Filed: September 18, 2008
    Publication date: August 4, 2011
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • Publication number: 20060280741
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF? inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF? inhibitors.
    Type: Application
    Filed: August 18, 2006
    Publication date: December 14, 2006
    Applicant: Immunex Corporation
    Inventors: Kendall Mohler, Dauphine Barone, Jacques Peschon, Mary Kennedy, John Pluenneke